Abstract
The deubiquitylase USP30 is an actionable target considered for treatment of conditions associated with defects in the PINK1-PRKN pathway leading to mitophagy. We provide a detailed cell biological characterization of a benzosulphonamide molecule, compound 39, that has previously been reported to inhibit USP30 in an in vitro enzymatic assay. The current compound offers increased selectivity over previously described inhibitors. It enhances mitophagy and generates a signature response for USP30 inhibition after mitochondrial depolarization. This includes enhancement of TOMM20 and SYNJ2BP ubiquitylation and phosphoubiquitin accumulation, alongside increased mitophagy. In dopaminergic neurons, generated from Parkinson disease patients carrying loss of function PRKN mutations, compound 39 could significantly restore mitophagy to a level approaching control values. USP30 is located on both mitochondria and peroxisomes and has also been linked to the PINK1-independent pexophagy pathway. Using a fluorescence reporter of pexophagy expressed in U2OS cells, we observe increased pexophagy upon application of compound 39 that recapitulates the previously described effect for USP30 depletion. This provides the first pharmacological intervention with a synthetic molecule to enhance peroxisome turnover.
Highlights
The ubiquitin-specific peptidase (USP) family of proteins represents an emerging focus for drug discovery efforts [1]
Inhibition of USP30 represents an actionable target to correct pathologies associated with PINK1 or PRKN defects, such as Parkinson disease or pulmonary fibrosis [7, 8]
In PD, this has been driven by the understanding that two PD-associated genes PINK1 and PRKN combine to promote mitophagy and that this pathway is deficient in patients bearing loss-of-function mutations [28]
Summary
The ubiquitin-specific peptidase (USP) family of proteins represents an emerging focus for drug discovery efforts [1]. Amongst this family, USP30 is unique in exclusively localizing to mitochondria and peroxisomes, by virtue of its transmembrane domain [2, 3, 4]. We and others have shown that USP30 localizes to peroxisomes and that its depletion can lead to elevation of pexophagy without any effect on bulk macroautophagy/ autophagy [4, 9]. Current tools to manipulate peroxisome turnover are limited to manipulation of lipids in the specific context of hepatocytes or crude approaches that stimulate general autophagy [12, 13, 14]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
